HIV Infections Clinical Trial
— InSTINCTOfficial title:
A Phase IV, Multicenter, Open and Randomized Study to Assess the Impact of the Change From Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With Type 1 HIV Infection. InSTINCT Study
Verified date | June 2024 |
Source | Fundacion SEIMC-GESIDA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
242 patients (121 patients in each of the two treatment arms) will be included with a confirmed diagnosis of HIV-1 infection and with a stable antiretroviral treatment during more than 48 weeks with dual therapy (DTG + 3TC)
Status | Completed |
Enrollment | 141 |
Est. completion date | January 16, 2024 |
Est. primary completion date | June 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men and women = 18 years - Confirmed and documented diagnosis of HIV-1 infection - Virological suppression of more than 48 weeks (confirmed with HIV RNA <50 copies / ml). The determination of the CV of a routine prior analysis of = 12 weeks prior to signature of consent. - ART in stable dual therapy (> 48 weeks) with DTG + 3TC - Signed informed consent - Negative pregnancy test in urine or blood Exclusion Criteria: - Inability to obtain written informed consent to participate in the study - Pregnant or breastfeeding women or those who intend to become pregnant during the study period and do not undertake to use proven contraceptive methods. - Any suspicion or confirmation of resistance to TAF, 3TC, FTC, DTG or BIC. In case of have a study of baseline resistance mutations prior to the start of ART has to rule out resistance to investigational drugs. - Patients with hypersensitivity to any excipient used with TAF, FTC, DTG or BIC - Any chronic autoimmune or inflammatory disease - Use of immunomodulatory or immunosuppressive agents, including steroids Chronic treatment with aspirin, statins and other anti-inflammatory agents - Any acute infection in the last 2 months - Estimated glomerular filtration rate (TFGe) <30 mg / ml / m2 measured by any of the formulas available. The determination of the TFGe of a previous routine analysis of = 12 weeks prior to signing the consent is allowed - Contraindication for the use of TAF - Clinical condition of the patient in rapid deterioration or the investigator considers that there is no reasonable hope that the patient will finish the study - Simultaneous participation in another clinical trial or research study that requires the need of treatment with other drugs outside the study or interfere with the visits of the same. - Any situation that, in the opinion of the investigator, may interfere with the patient's ability to meet the treatment schedule and protocol evaluations |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital General de Alicante | Alicante | |
Spain | H. Clinic i Provincial | Barcelona | |
Spain | Hospital de Bellvitge | Barcelona | |
Spain | Hospital Univ. Vall D'Hebron | Barcelona | |
Spain | Hospital Reina Sofia | Córdoba | |
Spain | Hospital Clínico San Carlos | Madrid | |
Spain | Hospital Fundación Jimenez Diaz | Madrid | |
Spain | Hospital Univ. de La Princesa | Madrid | |
Spain | Hospital Univ. La Paz | Madrid | |
Spain | Hospital Univ. Ramón y Cajal | Madrid | |
Spain | Hospital Virgen de las Nieves | Malá | |
Spain | Hospital Regional Carlos Haya | Málaga | |
Spain | Hospital Virgen de la Victoria | Málaga | |
Spain | Hospital de Santiago | Santiago De Compostela | |
Spain | Hospital Univ. Virgen del Rocio | Sevilla | |
Spain | Hospital Univ. Clínico de Valencia | Valencia | |
Spain | Hospital Univ. Lozano Blesa | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Fundacion SEIMC-GESIDA |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | sCD14 | Changes in sCD14 concentration | Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96 | |
Secondary | Changes in PCR-us | Inflammation (IL-6 signaling pathways): | Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96 | |
Secondary | Changes in sCD163 | Monocyte / macrophage activation | Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96 | |
Secondary | Changes in quinurenine / tryptophan ratio | IDO-1 induction | Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96 | |
Secondary | Changes in Dimer D | Coagulation | Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96 | |
Secondary | Changes in CD4/CD8 ratio | Inmunoactivation | Screening, basal, week 23, week 24, week 47, week 48, week 95 y week 96 | |
Secondary | Changes in CD4+ | Throughout all the study, an average of 100 weeks | ||
Secondary | Changes in viral suppression rates | Throughout all the study, an average of 100 weeks | ||
Secondary | Longitudinal trajectories of plasma biomarkers | The differences in the trajectories of soluble inflammatory markers by comparing the slopes of each biomarker between treatment arms. Longitudinal changes in each biomarker will be compared using linear or non-linear mixed models with random intercepts, depending on the normality of the data. | Throughout all the study, an average of 100 weeks | |
Secondary | Longitudinal trajectories of CD4/CD8 ratio | Throughout all the study, an average of 100 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |